SC
PFE icon

Swan Capital’s Pfizer PFE Stock Holding History

Swan Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Sell
11,171
-583
-5% -$15.3K 0.09% 37
2026
Q1 		$330K Buy
11,754
+435
+4% +$11.6K 0.12% 33
2025
Q4 		$282K Sell
11,319
-50
-0.4% -$1.26K 0.11% 35
2025
Q3 		$290K Buy
11,369
+2
+0% +$49 0.12% 34
2025
Q2 		$276K Buy
11,367
+1
+0% +$23 0.12% 37
2025
Q1 		$288K Buy
11,366
+1
+0% +$26 0.13% 32
2024
Q4 		$302K Buy
11,365
+263
+2% +$7.13K 0.15% 30
2024
Q3 		$321K Hold
11,102
– – 0.16% 30
2024
Q2 		$311K Buy
11,102
+28
+0.3% +$771 0.17% 30
2024
Q1 		$307K Buy
11,074
+272
+3% +$7.55K 0.17% 30
2023
Q4 		$311K Buy
10,802
+464
+4% +$14K 0.2% 26
2023
Q3 		$343K Buy
+10,338
New +$366K 0.27% 25

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swan Capital's PFE Position: Q2 2026 in Review

Swan Capital reduced its Pfizer (PFE) stake by 5% in Q2 2026, selling an estimated $15.3K and leaving 11,171 shares worth $269K. The position accounts for 0.09% of the portfolio, ranked #37.

Swan Capital first reported a position in PFE in Q3 2023 and has held it in 12 quarters since. The position peaked at $343K in Q3 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Swan Capital held 11,171 shares of Pfizer worth $269K as of Q2 2026.
  • Swan Capital sold 583 Pfizer shares in Q2 2026, an estimated $15.3K.
  • Pfizer made up 0.09% of Swan Capital's portfolio in Q2 2026, its #37 holding.
  • Swan Capital first reported a position in Pfizer in Q3 2023 and has held it in 12 quarters since.
  • Swan Capital's Pfizer position peaked at $343K in Q3 2023.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.